Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor
Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate safety and feasibility of neoadjuvant nivolumab plus
ipilimumab prior to standard therapy (surgery, chemotherapy or radiation therapy) in patients
with Neurofibromatosis Type 1 (NF1) and newly diagnosed pre-malignant and malignant
peripheral nerve sheath tumors (MPNST) for whom surgery for resection of tumor is indicated.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins